Background Increasing evidence from clinical outcomes studies suggest that cardiac resynchronisation therapy with defibrillation (CRT-D) is superior to implantable cardioverter defibrillator (ICD) therapy alone in patients with left ventricular dysfunction.
Methods We undertook a retrospective analysis of all ICD and CRT-D implants from April 2006 to July 2012. Cost data was obtained on an individual patient basis, derived from financial records of transactions between payers and the provider.
Results A total of 921 patients (aged 63±14 years (mean±SD), 49 (91%) male) underwent device implantation: 486 (53%) de novo CRT-D; 381 (41%) single/dual chamber ICD; and, 54 (6%) upgrade from ICD to CRT-D. In the upgrades from ICD to CRT-D, the median time from ICD to CRT-D implantation was 3.2 years. From the time prior to ICD implantation to prior to CRT-D, the LVEF decreased from 30±9.4% to 22±8.7% (p<0.001), the QRS duration increased from 133±34.9 ms to 158±29.3 ms (p=0.0003) and all patients had progressed to NYHA class III. In this upgrade group, the initial ICD implantation cost £846 864 (34 electives: £511 904; 20 non-electives: £334 960) and the upgrade to CRT-D cost £1 330 614 (44 electives: £1 046 364; 10 non-electives: £284 250), totalling £2 177 478 in implantation costs alone over a median of 3.2 years. If these 54 patients had a CRT-D at the initial implant, it would have cost £1 377 054 (34 electives: £808 554; 20 non-electives: £568 500). Therefore, this approach would have saved £800 424 in implantation costs alone.
Conclusions This study indicates that upgrading from ICD to CRT-D is costly. Our findings suggest that implantation of CRT-D in patients with known left ventricular dysfunction may be more cost-effective.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.